Der Ultimative Calyptemotivationsthread

Form 8-K for CALYPTE BIOMEDICAL CORP


--------------------------------------------------

3-Jun-2004

Other Events and Financial Statements & Exhibits


ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The Registrant (the "Company") on March 19, 2004 amended its prioragreement with Marr Technologies, B.V. ("Marr"), the Company's largeststockholder, whereby Marr agreed to purchase up to $15,000,000 of 5% PromissoryNotes (the "Promissory Notes") that the Company could issue between March 19,2004 and May 31, 2004. The Company did not issue any Promissory Notes duringthis period. On May 26, 2004, the Company entered into a second amendment to theagreement with Marr whereby Marr has now committed to purchase up to anaggregate of $5,000,000 of the Company's Promissory Notes, subject toadjustment, and has extended the availability period of the commitment throughDecember 31, 2004. The second amendment also provides that any notes issuedunder the agreement between June 1, 2004 and December 31, 2004 will bearinterest at a rate of 9% per annum. The Company may, but is not required to,issue up to the entire $5,000,000 commitment of 9% Promissory Notes under thesecond amendment to the agreement. Any 9% Promissory Note issued by the Companyunder the second amendment to the agreement will have a maturity date of May 31,2005. Proceeds from any issuance of the notes under the second amendment to theagreement may be used for general corporate purposes.

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »